Last updated on April 2016

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer


Brief description of study

Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be safely combined with pegylated liposomal doxorubicin in this indication.

Clinical Study Identifier: NCT02751918

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Yale University School of Medicine
New Haven, CT United States
  Connect »

Bayer Clinical Trials Contact

Oklahoma University Health Science Center
Oklahoma City, OK United States
  Connect »

Bayer Clinical Trials Contact

The Institute of Oncology
Chisinau, Moldova, Republic of
  Connect »